After 12 weeks , the mean ( 95 % CI ) percent changes from baseline in weekly hot flash frequency were as follows : placebo , -37.4 % ( -60.9 to -14.0 ) ; raloxifene , -14.2 % ( -37.7 to 9.3 ) ; paroxetine , -49.8 % ( -88.6 to -11.0 ) ; the mean ( 95 % CI ) percent changes in hot flash severity were as follows : placebo , -39.9 % ( -69.1 to -10.8 ) ; raloxifene , -9.6 % ( -38.8 to 19.6 ) ; paroxetine , -36.6 % ( -84.7 to 11.5 ) .